Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label phase III study of desloratadine in Japanese subjects with eczema/dermatitis and dermal pruritus
2017-000610-26Phase 3
- Sponsor
- Merck & Co.
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of desloratadine in atopic dermatitis (AD), dermatitis and pruritus (2 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in pruritus/itch score at Week 2.
02
Drugs
desloratadine
03
Conditions
atopic dermatitis (AD)dermatitispruritus
Beyond the preview
Go deeper on 2017-000610-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000610-26.